Myriad Genetics (MYGN) Common Equity: 2010-2025
Historic Common Equity for Myriad Genetics (MYGN) over the last 15 years, with Sep 2025 value amounting to $372.8 million.
- Myriad Genetics' Common Equity fell 49.05% to $372.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $372.8 million, marking a year-over-year decrease of 49.05%. This contributed to the annual value of $701.1 million for FY2024, which is 10.48% down from last year.
- Per Myriad Genetics' latest filing, its Common Equity stood at $372.8 million for Q3 2025, which was down 3.94% from $388.1 million recorded in Q2 2025.
- Over the past 5 years, Myriad Genetics' Common Equity peaked at $968.6 million during Q3 2021, and registered a low of $372.8 million during Q3 2025.
- In the last 3 years, Myriad Genetics' Common Equity had a median value of $731.7 million in 2024 and averaged $676.0 million.
- Its Common Equity has fluctuated over the past 5 years, first climbed by 9.85% in 2021, then crashed by 49.05% in 2025.
- Myriad Genetics' Common Equity (Quarterly) stood at $967.8 million in 2021, then dropped by 8.47% to $885.8 million in 2022, then decreased by 11.58% to $783.2 million in 2023, then fell by 10.48% to $701.1 million in 2024, then crashed by 49.05% to $372.8 million in 2025.
- Its Common Equity was $372.8 million in Q3 2025, compared to $388.1 million in Q2 2025 and $704.9 million in Q1 2025.